Latest Content

CTIM-76 received fast track designation from the FDA for pretreated platinum-resistant ovarian cancer.

Neoadjuvant THP demonstrated noninferiority compared with standard TCbHP in patients with stage II or III HER2-positive breast cancer.

Read our recap of top phase 1 and 2 breast cancer data announcements and highlights that may influence further clinical research and developments.

Pembrolizumab plus paclitaxel, with or without bevacizumab, is approved in the EU for pretreated platinum-resistant ovarian cancer with PD-L1 expression.

A trend toward improved OS was also observed when the dual immunotherapy regimen was added to TACE and lenvatinib in this patient population.

Kathleen Burns, MD, PhD, of has been elected as Fellow of the American Association for the Advancement of Science.

The FDA has granted traditional approval to brexucabtagene autoleucel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma.

Use of ruxolitinib before, during, and after allogeneic stem cell transplant was associated with low rates of GVHD in myelofibrosis.

The addition of palbociclib to maintenance HER2-directed and endocrine therapy improved PFS vs SOC therapy alone in HER2-positive advanced breast cancer.

Read a refresh of the top FDA news in breast cancer from March 2026, including anticipated approvals and a biosimilar approval.

A study identified genetic mutations tied to earlier diagnosis and faster progression of myelodysplastic syndromes.

Cogent Biosciences has submitted an NDA for bezuclastinib for patients with GIST who received prior imatinib.

The FDA has extended the PDUFA date for the Orca-T BLA to July 6, 2026.